Dr. Bollard received her medical degree at the University of Otago in Dunedin, New Zealand. She is board certified both in pediatrics and hematology. She worked in New Zealand and London, England, before moving to Houston, Texas, in 2000 where she was a Professor of Pediatrics, Medicine, and Immunology at Baylor College of Medicine (BCM) and the Director of the Texas Children’s Cancer and Hematology Center Pediatric Lymphoma Program. In August 2013, she was recruited to Washington, DC, to join Children’s National Health System and The George Washington University School of Medicine and Health Sciences. She is currently the Bosworth Chair for Cancer Biology, the Director of the Center for Cancer and Immunology Research, and the Director of the Program for Cell Enhancement and Technologies for Immunotherapy (CETI) at Children’s National Health System. She is a Professor of Pediatrics and of Microbiology, Immunology, and Tropical Medicine at The George Washington University and the Associate Center Director for Translational Research and Innovation at the GW Cancer Center. Dr. Bollard is a member of the American Society for Clinical Investigation (ASCI), is a past president of the International Society for Cellular Therapy (ISCT), and is the current President of the Foundation for the Accreditation of Cellular Therapy (FACT). She was a member of the Cellular, Tissues, and Gene Therapies Advisory Committee of the Food and Drug Administration (FDA) from 2015 to 2019 and in 2019 she became a member of the Frederick National Laboratory Advisory Committee (FNLAC) for the NIH and an ad hoc member of the Pediatric Oncologic Drugs Advisory Committee (ODAC) for the FDA. She was an associate editor for the journal Blood from 2014-2021 and is currently Editor in Chief of Blood Advances. She has >200 peer reviewed publications and has been independently NIH funded for over a decade. Her bench and translational research focuses on improving outcomes for patients after hematopoietic stem cell transplantation and on the development of novel cell therapies for cancer and virus-associated diseases.